semaglutide great hills Side Effects: What Patients Should Know in 2025 The Department of Veterans Affairs

The analysis of the SURPASS trials of tirzepatide revealed no association between weight reduction and gastrointestinal adverse events (229)

Food and Drug Administration (FDA) approved Rybelsus in September 2019 as the first oral GLP-1 receptor agonist for adults with type 2 diabetes

If your back pain is not being properly addressed, book in with one of our osteopaths.

Throughout the trial, researchers will track changes in participants' drinking habits, overall physical health and quality of life to assess whether the medication could eventually become a viable new treatment option for alcohol use disorder

To understand why, we need to look at how weight and lymphedema interact